|
|
Article: Biomira, Merck KGaA Report Failed Theratope Phase III Trial.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Biomira Inc.'s stock plunged 62.8 percent Tuesday when the company and its partner, Merck KGaA, released disappointing news regarding a large Phase III trial of the metastatic breast cancer vaccine, Theratope.
The companies said the trial failed to reach its two primary endpoints of time to disease progression and overall survival. However, the good news, Biomira said, is that a prestratified subset of women on hormonal treatment following chemotherapy appeared to show a favorable trend to improvement in survival.
Still, Biomira's stock (NASDAQ:BIOM) fell $2.51 Tuesday to close at $1.49.
Of the news, Alex McPherson, ...